title: Adult-to-adult right-lobe living donor liver transplantation in recipients with hepatitis B virus-related benign liver disease and high model end-stage liver disease scores.
abstract: OBJECTIVE
  We evaluated the safety and efficacy of adult-to-adult right-lobe living donor liver transplantation (ARL-LDLT) in HBV-related benign liver disease recipients with high model for end-stage liver disease (MELD) scores.
  
  
  METHODS
  The subjects of this study were 70 adult patients who underwent ARL-LDLT and 191 who underwent DDLT, for HBV-related end-stage liver diseases, between May 2002 and December 2009. Short-term outcomes were assessed by 30-day mortality and graft loss, parameters indicating graft dysfunction, length of hospital stay, and postoperative complications within 3 months. Long-term transplant outcomes were measured by graft- and patient survival and HBV recurrence rates at 1, 3, and 5 years.
  
  
  RESULTS
  There were no differences in donor outcomes or recipient short-term outcomes between the groups, although recipients with a high MELD score (Group H) had a higher incidence of pneumonia. High MELD score versus low MELD score recipients had similar 1-, 3-, and 5-year patient survival rates and post-transplant HBV recurrence rates. In the matched DDLT cases, a similar tendency was observed between group H and group L.
  
  
  CONCLUSIONS
  ARL-LDLT can be performed safely and effectively in high-MELD score patients with HBV-related benign liver disease; thus, a high MELD score may not contraindicate ARL-LDLT.
authors.affiliation: Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.forename: Lunan
authors.initials: L
authors.lastname: Yan
authors.forename: Yongqiong
authors.initials: Y
authors.lastname: Tan
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Tianfu
authors.initials: T
authors.lastname: Wen
authors.forename: Jiayin
authors.initials: J
authors.lastname: Yang
authors.forename: Jichun
authors.initials: J
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D058625:End Stage Liver Disease / Q000401:mortality / Q000601:surgery*; D005260:Female; D006085:Graft Survival; D019694:Hepatitis B, Chronic / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents